LFVN Lifevantage (LFVN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000849146
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
39
13F, latest reported quarter
What the filings say about LFVN
Insiders, 180 days
-$129.0K net sold
1 buyer · 2 sellers · 0% of sales under a 10b5-1 plan
Lifevantage insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Lifevantage Corp insiders sold a net $129.0K of stock across 62 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 buys), the last on Jun 15, 2026.
- +3.6% median (+8.8% mean) 90-day return after 13 previous buys.
- The trade is 0.7% of the 138,244 shares held after it.
- No other insider bought within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lewis Darwin bought about $6.1K of LFVN under a 10b5-1 plan on Sep 15, 2026; 39 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 11, 2026.
- The trade is 7.4% of the 120,162 shares held after it.
- No other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Sales Officer Cunningham Kristen sold about $55.0K of LFVN on Sep 14, 2026; 39 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 129,063 shares held after it.
- No other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Sales Officer Cunningham Kristen sold about $641 of LFVN on Sep 11, 2026; 39 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Mar 16, 2026.
- +4.9% median (+10.0% mean) 90-day return after 12 previous buys.
- The trade is 0.5% of the 137,268 shares held after it.
- No other insider bought within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lewis Darwin bought about $6.1K of LFVN on Jun 15, 2026; 39 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (3 buys, 9 sales), the last on Nov 19, 2025.
- +15.2% median (+8.7% mean) 90-day return after 3 previous buys.
- The trade is 24.0% of the 41,625 shares held after it.
- No other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BEINDORFF MICHAEL A sold about $85.5K of LFVN on Jun 3, 2026; 39 funds added in the latest 13F quarter.62 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$129.0K over 180 days
-$49.6K over 90 days
more than 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
39 funds bought in last quarter
below 58% of Pharma & Biotech
Revenue
-20.1% year over year
below 69% of Pharma & Biotech
Margin
2.8% net margin
more than 76% of Pharma & Biotech
Buybacks
$2.0M repurchased, FY to 2026-06-30
below 84% of Pharma & Biotech
Short interest
11.4% of the float short (float per yahoo 2026-10-27) · 28.8 days to cover · settled 2026-10-15
more than 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LFVN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LFVN: institutional holders (13F)
13F holdings, latest reported quarter
1,878,411 sh
$11.7M
669,418 sh
$4.2M
429,203 sh
$2.7M
268,605 sh
$1.7M
256,296 sh
$1.6M
Congress trades in LFVN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LFVN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LFVN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Quant Small-Cap Quality Value ETF
$54.6K position · as of 2026-06-30
0.2%
iShares Micro-Cap ETF
$228.4K position · as of 2026-06-30
0.0%
Applied Finance IVS US SMID ETF
$3.8K position · as of 2026-06-30
0.0%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$128.7K position · as of 2026-05-31
0.0%
EA Bridgeway Omni Small-Cap Value ETF
$146.8K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity Fund
$12.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Steven R. Fife
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.8M
$7.5M
$1.0M
+106%
n/a
2023
$2.3M
$3.0M
$704.0K
+60%
n/a
2022
$2.4M
$2.7M
$718.2K
-39%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $129.0K sold by insiders over 180 days, 39 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LFVN financials
Revenue growth
-20.1%
XBRL, annual
Net margin
2.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$182.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LFVN
| FY Jun 2026 | $182.6M |
| FY Jun 2025 | $228.5M |
| FY Jun 2024 | $200.2M |
| FY Jun 2023 | $213.4M |
| FY Jun 2022 | $206.4M |
| Jun 2026 | $42.4M |
| Mar 2026 | $43.7M |
| Dec 2025 | $48.9M |
| Sep 2025 | $47.6M |
| Jun 2025 | $55.1M |
| Mar 2025 | $58.4M |
| Dec 2024 | $67.8M |
| Sep 2024 | $47.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LFVN
| FY Jun 2026 | +2.8% |
| FY Jun 2025 | +4.3% |
| FY Jun 2024 | +1.5% |
| FY Jun 2023 | +1.2% |
| FY Jun 2022 | +1.5% |
| Jun 2026 | +3.0% |
| Mar 2026 | +3.1% |
| Dec 2025 | +0.6% |
| Sep 2025 | +4.5% |
| Jun 2025 | +3.6% |
| Mar 2025 | +5.9% |
| Dec 2024 | +3.8% |
| Sep 2024 | +3.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$6.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LFVN
| FY Jun 2026 | $6.7M |
| FY Jun 2025 | $10.5M |
| FY Jun 2024 | $10.0M |
| FY Jun 2023 | $3.8M |
| FY Jun 2022 | $6.4M |
| Jun 2026 | $3.7M |
| Mar 2026 | $4.0M |
| Dec 2025 | $1.7M |
| Sep 2025 | -$2.7M |
| Jun 2025 | $835.0K |
| Mar 2025 | $1.9M |
| Dec 2024 | $8.7M |
| Sep 2024 | -$932.0K |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2019-06-30 (85 months older than the period end) plus current 2020-06-30 (73 months older than the period end); equity 2026-06-30
Debt to equity LFVN
| FY Jun 2026 | 0.00x |
| FY Jun 2025 | 0.00x |
| FY Jun 2024 | 0.00x |
| FY Jun 2023 | 0.00x |
| FY Jun 2022 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt LFVN
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+14.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LFVN
| FY Jun 2026 | +14.9% |
| FY Jun 2025 | +32.3% |
| FY Jun 2024 | +9.7% |
| FY Jun 2023 | +7.7% |
| FY Jun 2022 | +9.1% |
| Jun 2026 | +14.9% |
| Mar 2026 | +17.1% |
| Dec 2025 | +25.0% |
| Sep 2025 | +33.3% |
| Jun 2025 | +32.3% |
| Mar 2025 | +30.1% |
| Dec 2024 | +25.7% |
| Sep 2024 | +14.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LFVN
| FY Jun 2026 | +7.6% |
| FY Jun 2025 | +14.8% |
| FY Jun 2024 | +4.6% |
| FY Jun 2023 | +3.7% |
| FY Jun 2022 | +4.2% |
| Jun 2026 | +7.6% |
| Mar 2026 | +8.3% |
| Dec 2025 | +12.1% |
| Sep 2025 | +16.5% |
| Jun 2025 | +14.8% |
| Mar 2025 | +13.2% |
| Dec 2024 | +11.2% |
| Sep 2024 | +6.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+32.8%
operating income after a 16.4% effective tax rate, over long-term 2019-06-30 (85 months older than the period end) plus current 2020-06-30 (73 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital LFVN
| FY Jun 2026 | +32.8% |
| FY Jun 2025 | +83.0% |
| FY Jun 2024 | +26.4% |
| FY Jun 2023 | +22.2% |
| FY Jun 2022 | +40.4% |
| Jun 2026 | +32.8% |
| Mar 2026 | +37.0% |
| Dec 2025 | +58.8% |
| Sep 2025 | +85.2% |
| Jun 2025 | +83.0% |
| Mar 2025 | +84.7% |
| Dec 2024 | +82.6% |
| Sep 2024 | +45.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LFVN
| FY Jun 2026 | +14.1% |
| FY Jun 2025 | +29.5% |
| FY Jun 2024 | +10.3% |
| FY Jun 2023 | +9.3% |
| FY Jun 2022 | +15.4% |
| Jun 2026 | +14.1% |
| Mar 2026 | +15.2% |
| Dec 2025 | +21.5% |
| Sep 2025 | +29.0% |
| Jun 2025 | +29.5% |
| Mar 2025 | +31.0% |
| Dec 2024 | +26.9% |
| Sep 2024 | +15.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
14.40x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing LFVN
| FY Jun 2026 | 15.60x |
| FY Jun 2025 | 17.68x |
| FY Jun 2024 | 27.91x |
| FY Jun 2023 | 21.75x |
| FY Jun 2022 | 18.12x |
| Jun 2026 | 15.60x |
| Mar 2026 | 9.60x |
| Dec 2025 | 10.27x |
| Sep 2025 | 12.64x |
| Jun 2025 | 17.68x |
| Mar 2025 | 21.13x |
| Dec 2024 | 31.30x |
| Sep 2024 | 37.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$52.0M
market value at close 2026-10-26 on 2026-08-26 shares, plus long-term 2019-06-30 (85 months older than the period end) plus current 2020-06-30 (73 months older than the period end), minus cash 2025-06-30
Enterprise value LFVN
| FY Jun 2026 | $58.5M |
| FY Jun 2025 | $144.5M |
| FY Jun 2024 | $64.7M |
| FY Jun 2023 | $34.1M |
| FY Jun 2022 | $34.6M |
| Jun 2026 | $58.5M |
| Mar 2026 | $35.1M |
| Dec 2025 | $58.0M |
| Sep 2025 | $103.3M |
| Jun 2025 | $144.5M |
| Mar 2025 | $166.1M |
| Dec 2024 | $202.7M |
| Sep 2024 | $133.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield LFVN
| FY Jun 2026 | +8.5% |
| FY Jun 2025 | +6.4% |
| FY Jun 2024 | +12.2% |
| FY Jun 2023 | +6.8% |
| FY Jun 2022 | +11.7% |
| Jun 2026 | +8.5% |
| Mar 2026 | +6.8% |
| Dec 2025 | +2.2% |
| Sep 2025 | +7.0% |
| Jun 2025 | +6.4% |
| Mar 2025 | +6.5% |
| Dec 2024 | +5.9% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -46%, PEG needs growth
PEG, trailing LFVN
| FY Jun 2026 | n/a |
| FY Jun 2025 | 0.08x |
| FY Jun 2024 | 1.86x |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.44x |
| Sep 2025 | 0.09x |
| Jun 2025 | 0.08x |
| Mar 2025 | 0.14x |
| Dec 2024 | 0.22x |
| Sep 2024 | 0.63x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $182.6M | $228.5M | $200.2M | $213.4M |
| Gross profit | $141.6M | $183.7M | $158.7M | $170.0M |
| Operating income | $6.1M | $12.2M | $4.3M | $4.3M |
| Net income | $5.1M | $9.8M | $2.9M | $2.5M |
| EPS (diluted) | 0.40 | 0.75 | 0.23 | 0.20 |
| Operating cash flow | $10.2M | $11.9M | $12.2M | $6.8M |
| Cash | n/a | $20.2M | $16.9M | $21.6M |
| Buybacks | $2.0M | $3.1M | $6.4M | $822.0K |
| Dividends paid | $2.3M | $2.1M | $6.9M | $1.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
LFVN Stock Sonar score 6/7 axes
Find similar shapesCompareLFVN ranks highest on financial health (99th percentile) and profitability (85th), and lowest on growth (31st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LFVN filings, in plain words
Are Lifevantage insiders buying or selling LFVN?
In the 180 days to 2026-10-28, Lifevantage insiders were net sellers, a net $129.0K: $12.1K of purchases and $141.1K of sales reported on Form 4, by 1 buyer and 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Lifevantage insiders were net sellers of LFVN, a net $129.0K across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. Sales outweighed purchases more than tenfold by value. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
